September 6, 2013 - The court approved the settlement.
September 5, 2013 - The court held a final settlement hearing.

May 1, 2013 - The court preliminarily approved the settlement.

January 31, 2013 - Parties filed a stipulation of settlement.

September 26, 2011 - The court denied the defendants' motion to dismiss.

November 24, 2010 - The defendants filed a motion to dismiss.

September 27, 2010 - The lead plaintiff filed an amended complaint.

July 28, 2010 - The lead plaintiff and lead counsel were appointed.

September 18, 2009 - Lead plaintiff motions were filed.

July 17, 2009 - An investor in shares of Matrixx Initiatives Inc (NASDAQ: MTXX) filed a lawsuit in the U.S. District Court for the District of Arizona against Matrixx Initiatives Inc over alleged violations of Federal Securities Laws.

According to the complaint the plaintiff alleges that between December 22, 2007 and June 15, 2009, Matrixx Initiatives Inc and other defendants failed to disclose material adverse facts concerning Matrixx Initiatives Inc’s operational well-being and future prospects.

Matrixx Initiatives Inc has recalled it's Zicam nasal products, but Matrixx Initiatives Inc has been investigated by the SEC with respect to its marketing practices, and according to the investigation it is believed that information surrounding the Zicam line of products, as well as Matrixx Initiatives Inc liability in connection with these products, was not reaching Matrixx Initiatives Inc's shareholders. On June 13, the FDA advised consumers to stop using three Matrixx Initiatives Inc-manufactured over-the-counter cold remedy products marketed under the Zicam name because they are associated with the loss of smell, which may be long-lasting and permanent. According to the FDA, as of Dec. 2007, Matrixx Initiatives Inc was required to provide reports of adverse reactions to the agency per the Dietary Supplement and Nonprescription Drug Consumer Protection Act.

On June 16, 2009 Matrixx Initiatives Inc announced that it has received a Warning Letter from the Food and Drug Administration (the FDA). The FDA has asserted that Matrixx Initiatives Inc is in violation of its regulations by failing to file a new drug application for its Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs and that those products are misbranded under their regulations for failing to adequately warn of risks. The FDA informed Matrixx Initiatives Inc it concluded that certain Zicam products may pose serious risks to consumers who use them, and that Matrixx Initiatives Inc marketing practices violate several laws relating to the products, so the investigation. Matrixx Initiatives Inc stated in its press release that “Since Zicam Cold Remedy intranasal Cold Remedy products were first introduced in the market in 1999, more than 35 million retail units representing over 1 billion doses have been sold “ and it “believes these products are safe and do not cause insomnia”, but then announced in a second press release on the same day that “Matrixx Initiatives Inc Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel” as “Consumer safety is and has always been the company's top priority”.

Then on June 22, 2009 nearly 120 individual claims were filed in Arizona Superior Court against Matrixx Initiatives Inc on behalf of individuals from 32 states, from Hawaii to a U.S. contractor in Afghanistan, as well as for a dozen Arizona residents who reported side effects ranging from a complete loss of smell and taste, to diminished senses of smell. The FDA stated in its letter from June 16, 2009 that the agency is aware that Matrixx Initiatives Inc appears to have more than 800 reports related to loss of sense of smell associated with Zicam Cold Remedy intranasal products and directed Matrixx Initiatives Inc”to arrange submission of all reports related to loss of sense of smell associated with Zicam Cold Remedy intranasal products and to indicate which of these reports have been previously submitted to the FDA. Upon release of this letter by the FDA, so the investigation, Matrixx Initiatives Inc stock (NASDAQ: MTXX) declined from approximately $19 per share to less than $7 per share. On July 23, 2009, Matrixx Initiatives Inc acknowledged the Securities and Exchange Commission is launching an informal inquiry.

Matrixx Initiatives Inc is located in Phoenix, Arizona . It develops, produces, markets and sells over-the-counter (OTC) healthcare products with an emphasis on those that utilize delivery systems that provide consumers with Better Ways to Get Better. Through its subsidiary, Zicam, LLC, the Company markets and sells products under the Zicam brand. Shares ofMatrixx Initiatives Inc (NASDAQ:MTXX) continued to decline on Monday, July 06, 2009, and closed at $6.05 per share, down from a 52weekHigh of $19.74 per share, and over $21.50 per share in 2007. Matrixx Initiatives Inc reported Total Revenue of $100.97million and a net income of $10.43million in 2007 and $111.63million and a net income of $13.86million in 2008.